MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1126/scitranslmed.adv2293

Медицинская библиотека · Science translational medicine · 2025

Metabolism-programming mRNA-lipid nanoparticles remodel the immune microenvironment to improve immunotherapy against MAFLD.

Yu Xinyang, Qi Shaolong, Cao Wanyue, Cheng Meiqi, Zhang Wenjie, Wang Yangfan, Zheng Rujia, Jin Gaowei, Gao Xiaomin, Lu Meixin, Lei Jiaqi, Peng Kun, Su Xinhui, Zhang Qi, Yu Guocan

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Metabolic dysfunction-associated fatty liver disease (MAFLD), a leading cause of hepatocellular carcinoma (HCC), poses a formidable therapeutic challenge because of the metabolic stress-induced aberrant immune microenvironment. However, no effective pharmacological therapies for the liver microenvironment remodeling in MAFLD are now available. Here, we developed a lipid nanoparticle (Def-LNP) that incorporates vitamin E-derived phosphatidylcholine (VEPC). Def-LNP effectively ameliorated the hepatic oxidative microenvironment to achieve sustained localized expression of target mRNA in hepatocytes in preclinical models, outperforming a commercially used LNP formulation. In vivo delivery efficiency, stability, and biosafety of Def-LNP were validated in various mammalian models, including mice, pigs, and nonhuman primates. Using clinical samples, we identified a pronounced correlation between T cell protein tyrosine phosphatase (TCPTP) and MAFLD pathogenesis. The administration of Def-LNP loaded with TCPTP-encoding mRNA (Def-LNP@mRNATCPTP) suppressed signal transducer and activator of transcription signaling in the hepatocytes of MAFLD mice, leading to hepatic metabolic reprogramming and immunological reconfiguration, a characteristic that is prominently lacking in conventional mRNA-based protein replacement therapy. In preclinical models, the administration of Def-LNP@mRNATCPTP successfully eliminated steatohepatitis, impeded hepatocarcinogenesis, and improved the therapeutic responsiveness of HCC to cancer vaccine and immune checkpoint blockade therapy. Def-LNP@mRNATCPTP represents a potential therapeutic strategy for MAFLD and MAFLD-related HCC, potentially offering treatment paradigms for immunotherapy for HCC and metabolic liver diseases.

Для цитирования: Yu Xinyang, Qi Shaolong, Cao Wanyue, Cheng Meiqi, Zhang Wenjie, Wang Yangfan, Zheng Rujia, Jin Gaowei, Gao Xiaomin, Lu Meixin, Lei Jiaqi, Peng Kun, Su Xinhui, Zhang Qi, Yu Guocan. Metabolism-programming mRNA-lipid nanoparticles remodel the immune microenvironment to improve immunotherapy against MAFLD.. Science translational medicine. 2025. DOI: 10.1126/scitranslmed.adv2293.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.